Generation of anti-NAG-2 mAb from patients' memory B cells: Implications for a novel therapeutic strategy in systemic sclerosis

International Immunology

Volumn 22, Issue 5, 2010, Pages 367-374

  Traggiai, Elisabetta ^a   Lunardi, Claudio ^b   Bason, Caterina ^b   Dolcino, Marzia ^a   Tinazzi, Elisa ^b   Corrocher, Roberto ^b   Puccetti, Antonio ^a,c  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Human mAb; Memory B cells; NAG 2; Systemic sclerosis

Indexed keywords

IMMUNOGLOBULIN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; NAG 2 ANTIBODY; PROTEIN NAG 2; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY PRODUCTION; ANTIGEN BINDING; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; APOPTOSIS; B-LYMPHOCYTES; CELL PROLIFERATION; DRUG DESIGN; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; MALE; MEMBRANE PROTEINS; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 77953997877     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxq016     Document Type: Article

References (30)

1. Seibold, J. R. 2001. Scleroderma. In Ruddy, S., Harris, E. D., and Sledge, C. B., eds, Kelly's Textbook of Rheumatology, 6th edn, p.1211. Saunders, Philadelphia, PA.
2. Sgonc, R., Gruschwitz, M. S., Dietrich, H., Recheis, H., Gershwin, M. E. and Wick, G. 1996. Endothelial cell apoptosis is a primary event underlying skin lesions in avian and human scleroderma. J. Clin. Invest. 98:785.
3. Chizzolini, C., Raschi, E., Rezzonico, R. et al. 2002. Autoanti-bodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum. 46:1602.
4. Terrier, B., Tamby, M. C., Camoin, L. et al. 2008. Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 177:1128.
5. Baroni, S. S., Santillo, M., Bevilacqua, F. et al. 2006. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N. Engl. J. Med. 354:2667.
6. Lunardi, C., Bason, C., Navone, R. et al. 2000. Systemic sclerosis IgG autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat. Med. 6:1183.
7. Tachibana, I., Bodorova, J., Berditchevski, F., Zutter, M. M. and Hemler, M. E. 1997. NAG-2, a novel transmembrane-4 superfamily (TM4SF) protein that complexes with integrins and other TM4SF proteins. J. Biol. Chem. 272:29181.
8. Arnos, Y., Amital, H., Guiducci, S. et al. 2009. The role of infections in the immunopathogenesis of systemic sclerosis-evidence from serological studies. Ann. N. Y. Acad. Sci. 1173:627.
9. Zakrzewska, K., Corcioli, F., Carlsen, K. M. et al. 2009. Human parvovirus B19 (B19V) infection in systemic sclerosis patients. Intervirology 52:279.
10. Randone, S. B., Guiducci, S. and Cerinic, M. M. 2008. Systemic sclerosis and infections. Autoimmun. Rev. 8:36.
11. Lunardi, C., Dolcino, M., Peterlana, D. et al. 2006. Antibodies against human cytomegalovirus in the pathogenesis of systemic sclerosis: a gene array approach. PLoS Med. 3:e2.
12. Traggiai, E., Becker, S., Subbarao, K. et al. 2004. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med. 10:871.
13. Lanzavecchia, A., Bernasconi, N., Traggiai, E., Ruprecht, C. R., Corti, D. and Sallusto, F. 2006. Understanding and making use of human memory B cells. Immunol. Rev. 211:303.
14. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutics Criteria Committee1980. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 21:581.
15. Wellings, D. A. and Atherton, E. 1997. Standard FMOC protocols. Meth. Enzymol. 289:44.
16. Jun, J. B., Kuechle, M., Min, J. et al. 2005. Scleroderma fibroblasts demonstrate enhanced activation of Akt (protein kinase B) in situ. J. Invest. Dermatol. 124:298.
17. Bujor, A. M., Pannu, J., Bu, S., Smith, E. A., Muise-Helmericks, R. C. and Trojanowska, M. 2008. Akt blockade downregulates collagen and upregulates MMP1 in human dermal fibroblasts. J. Invest. Dermatol. 128:1906.
18. Classen, J. F., Henrohn, D., Rorsman, F., Lennartsson, J., Lauwerys, B. R. and Wikström, G. 2009. Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum. 60:1137.
19. Loizos, N., LaRiccia, L., Weiner, J. et al. 2009. Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera. Arthritis Rheum. 60:1145.
20. Balda, E., Simeón-Aznar, C. P., Ordi-Ros, J. et al. 2008. Anti-PDGFRA antibodies measured by non-bioactivity assays are not specific for systemic sclerosis. Ann. Rheum. Dis. 67:1027.
21. Denton, C. P., Engelhart, M., Tvede, N. et al. 2009. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann. Rheum. Dis. 68:1433.
22. Allanore, Y., Devos-Francxois, G., Caramella, C., Boumier, P., Jounieaux, V. and Kahan, A. 2006. Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann. Rheum. Dis. 65:834.
23. McGonagle, D., Tan, A. L., Madden, J. et al. 2008. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology 47:552.
24. Denton, C. P., Merkel, P. A., Furst, D. E. et al. 2007. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum. 56:323.
25. Bibi, Y. and Gottlieb, A. B. 2008. A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis. J. Am. Acad. Dermatol. 59:654.
26. Distler, J. H., Jüngel, A., Huber, L. C. et al. 2007. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 56:311.
27. Pannu, J., Asano, Y., Nakerakanti, S. et al. 2008. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis Rheum 58:2528.
28. Van Daele, P. L., Dik, W. A., Thio, H. B. et al. 2008. Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis Rheum. 58:2549.
29. Van Laar, J. M., Farge, D. and Tyndall, A. 2008. Stem cell transplantation: a treatment for severe systemic sclerosis? Ann. Rheum. Dis. 67:35.
30. Farge, D., Nash, R. and Laar, J. M. 2008. Autologous stem cell transplantation for systemic sclerosis. Autoimmunity 28:1.